Literature DB >> 12539230

Lesions missed on prostate biopsies in cases sent in for consultation.

Joseph D Kronz1, Rolando Milord, Robb Wilentz, Edward G Weir, Stephanie R Schreiner, Jonathan I Epstein.   

Abstract

BACKGROUND: There are no reports on how often lesions are missed on prostate needle biopsies.
METHODS: Over a 10-month period, 8/99 to 5/00, 3,251 prostate biopsy cases were seen in consultation.
RESULTS: We identified 87 (2.7%) patients with missed lesions (n = 9 academic hospitals; n = 44 community hospitals; n = 34 commercial labs). Overall, 119 lesions were missed in 87 patients. Missed lesions were as follows: small atypical glands suspicious for cancer (41 lesions in 35 patients), prostatic adenocarcinoma (39 cancers in 32 patients), high grade prostatic intraepithelial neoplasia (HGPIN) (34 lesions in 30 patients), and HGPIN with adjacent small atypical glands (five lesions in five patients)--some men with more than one type of missed lesion. Detection of the missed lesions would have resulted in either: a definite change in care in 15 of 3,251 (0.5%) patients or a possible change in care (bilateral cancer vs. unilateral cancer; HGPIN vs. atypical) in 17 (0.5%) patients. In 21 (24%) of the cases, the slides were seen by at least two pathologists prior to consultation at our hospital.
CONCLUSIONS: Although the number of prostate biopsies with missed lesions in a consult-based population of prostate biopsies appears relatively high (2.7%), the detection of the missed lesions would have only effected a definite change in care in 0.5% of all patients or a possible change in care in another 0.5% of patients. Our data underestimates missed lesions, as the entire specimen was not submitted for review in 41% of cases. Although our incidence of missed lesions gives some indication as to the magnitude of the problem, it cannot be equated with the risk of missing lesions in unselected cases. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12539230     DOI: 10.1002/pros.10182

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer.

Authors:  Muhammad A Bulbul; Yaser El-Hout; Maurice Haddad; Ayman Tawil; Ali Houjaij; Nizar Bou Diab; Oussama Darwish
Journal:  Can Urol Assoc J       Date:  2007-09       Impact factor: 1.862

2.  Independent real-world application of a clinical-grade automated prostate cancer detection system.

Authors:  Leonard M da Silva; Emilio M Pereira; Paulo Go Salles; Ran Godrich; Rodrigo Ceballos; Jeremy D Kunz; Adam Casson; Julian Viret; Sarat Chandarlapaty; Carlos Gil Ferreira; Bruno Ferrari; Brandon Rothrock; Patricia Raciti; Victor Reuter; Belma Dogdas; George DeMuth; Jillian Sue; Christopher Kanan; Leo Grady; Thomas J Fuchs; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2021-04-27       Impact factor: 7.996

3.  An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy.

Authors:  Sudhir Perincheri; Angelique Wolf Levi; Romulo Celli; Peter Gershkovich; David Rimm; Jon Stanley Morrow; Brandon Rothrock; Patricia Raciti; David Klimstra; John Sinard
Journal:  Mod Pathol       Date:  2021-03-29       Impact factor: 7.842

4.  Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies.

Authors:  Patricia Raciti; Jillian Sue; Rodrigo Ceballos; Ran Godrich; Jeremy D Kunz; Supriya Kapur; Victor Reuter; Leo Grady; Christopher Kanan; David S Klimstra; Thomas J Fuchs
Journal:  Mod Pathol       Date:  2020-05-11       Impact factor: 8.209

5.  Interobserver Variability in the Diagnosis of High-Grade Prostatic Intraepithelial Neoplasia in a Tertiary Hospital in Northern Jordan.

Authors:  Najla Aldaoud; Amer Hallak; Nour Abdo; Samir Al Bashir; Noor Marji; Ashley Graboski-Bauer
Journal:  Clin Pathol       Date:  2020-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.